1. Harbeck N, Gnant M (2017) Breast cancer. Lancet. 389:1134-1150. https://doi.org/10.1016/S0140-6736(16)31891-8.
2. Folkman J (2006) Angiogenesis. Annu Rev Med. 57:1-18. https://doi.org/10.1146/annurev.med.57.121304.131306.
3. Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, Fan M, Li J, Wang B, Wang Z, Zhang Q, Sun S, Liao C (2014) Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 135:1961-1969. https://doi.org/10.1002/ijc.28829.
4. Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z, Wang B, Chen X, Yu H (2014) Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer.14:820. https://doi.org/10.1186/1471-2407-14-820.
5. Lü HM, Zhang MW, Niu LM, Zeng HA, Yan M (2018) [Clinical observation of apatinib mesylate for the treatment of multi-drug resistant advanced breast cancer]. Zhonghua Yi Xue Za Zhi. 98:1246-1249. Chinese. https://doi.org/10.3760/cma.j.issn.0376-2491.2018.16.012.
6. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus
bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666-2676. https://doi.org/10.1056/NEJMoa072113.
7. Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA, Miles DW (2011) Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer. 47:2387-95. https://doi.org/10.1016/j.ejca.2011.06.018.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228-247. https://doi.org/10.1016/j.ejca.2008.10.026.
9. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol.608:1-22. https://doi.org/10.1007/978-0-387-74039-3_1.
10. Araki K, Miyoshi Y (2018) Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 25:392-401. https://doi.org/10.1007/s12282-017-0812-x.
11. Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA (2009) Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol. 27:4693-4700. https://doi.org/10.1200/JCO.2008.21.4163.
12. Pernas S, Tolaney SM (2019) HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 11:1758835919833519. https://doi.org/10.1177/1758835919833519.
13. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 30:2718-2724. https://doi.org/10.1200/JCO.2011.39.0708.
14. Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA 3rd, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M (2013) Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer. 49:2621-2632. https://doi.org/10.1016/j.ejca.
15. Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 30:870-884. https://doi.org/10.1007/s12325-013-0060-1. Epub 2013 Oct 25.
16. André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol.15:580-591. https://doi.org/10.1016/S1470-2045(14)70138-X.
17. Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M (2014) Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 7:ra29. https://doi.org/10.1126/scisignal.2005125.
18. Li Q, Wang Y, Jia W, Deng H, Li G, Deng W, Chen J, Kim BYS, Jiang W, Liu Q, Liu J (2020) Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clin Cancer Res.26:1712-1724. https://doi.org/10.1158/1078-0432.CCR-19-2179.
19. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182-1186. https://doi.org/10.1056/NEJM197111182852108.
20. Folkman J (1995) Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. Dec 28;333(26):1757-1763. https://doi.org/10.1056/NEJM199512283332608.
21. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology. 69 Suppl 3:4-10. https://doi.org/10.1159/000088478.
22. Santos LV, Cruz MR, Lopes Gde L, Lima JP (2015) VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 151(3):481-489. https://doi.org/10.1007/s10549-015-3410-7.
23. Delli Carpini J, Karam AK, Montgomery L (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis.13:43-58. https://doi.org/ 10.1007/s10456-010-9163-3.
24. Kümler I, Christiansen OG, Nielsen DL(2014) A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev. 40:960-973. https://doi: 10.1016/j.ctrv.2014.05.006.
25. Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH, Wilcken N (2013) Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev.12:CD008792. https://doi.org/10.1002/14651858.CD008792.pub2.